Latest Ratios: P/E Ratio 35.6x · EV/EBITDA N/A · ROE 3.8%. (2024–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Market Cap | $262M | $203M | $245M |
| Enterprise Value | $261M | $202M | $243M |
| P/E Ratio → | 35.57 | 35.27 | 183.76 |
| P/S Ratio | — | — | — |
| P/B Ratio | 1.05 | 1.04 | 1.31 |
| P/FCF | — | — | — |
| P/OCF | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | — | — | 243499149.28 |
| EV / EBIT | — | — | — |
| EV / FCF | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross Margin | — | — | — |
| Operating Margin | — | — | — |
| Net Profit Margin | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| ROE | 3.8% | 3.8% | 0.0% |
| ROA | 3.7% | 3.7% | 0.0% |
| ROIC | -0.5% | -0.5% | — |
| ROCE | -0.6% | -0.6% | -0.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | — | — | 19320.26 |
| Net Debt / Equity | — | -0.01 | -0.01 |
| Net Debt / EBITDA | — | — | -1345220.00 |
| Debt / FCF | — | — | — |
| Interest Coverage | — | — | — |
Net cash position: cash ($1M) exceeds total debt ($11824)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Current Ratio | 1.19 | 1.19 | 2.14 |
| Quick Ratio | 1.19 | 1.19 | 2.14 |
| Cash Ratio | 1.10 | 1.10 | 1.87 |
| Asset Turnover | — | — | — |
| Inventory Turnover | — | — | — |
| Days Sales Outstanding | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Earnings Yield | 2.8% | 2.8% | 0.5% |
| FCF Yield | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $19M | $25M |
Liquidation deadline execution risk
According to recent market data, OACC trades at a P/B ratio of 1.05, suggesting that investors are pricing the entity primarily as a cash-equivalent vehicle rather than an operating business with growth prospects, as evidenced by the lack of meaningful P/E or EV/EBITDA multiples in current filings.
The current valuation reflects the market's focus on the trust account's net asset value rather than future earnings potential. Investors should monitor whether this premium to cash persists as the liquidation deadline approaches, as any significant deviation may indicate speculative interest in the sponsor's deal-sourcing capabilities.
Based on the 2026Q1 financial statements, OACC's current ratio has deteriorated to 0.87, indicating that the company's immediate liquid assets are insufficient to cover short-term liabilities, a trend that warrants further investigation as the entity continues to burn cash while searching for a viable life sciences target.
The decline from a current ratio of 2.14 in 2024Q4 suggests that the company is consuming its operating capital faster than it is replenishing it through interest income. This tightening liquidity buffer may force management to prioritize deal completion over optimal target selection to avoid a forced liquidation scenario.
As reported in quarterly filings, OACC's ROIC has trended into negative territory, reaching -0.2% in 2026Q1, which is consistent with a pre-revenue shell company that incurs administrative costs without generating the operational returns necessary to offset the capital deployed for maintaining its public listing status.
The persistent negative ROIC highlights the inherent inefficiency of holding capital in a shell structure while awaiting a business combination. Investors should interpret these returns not as a failure of management, but as the unavoidable cost of maintaining the optionality provided by the Oaktree sponsor network.
The most commonly misapplied metric for OACC is the P/E ratio, which, at 35.57, obscures the fact that the company generates no core revenue and that its net income is entirely derived from non-operating interest income, rendering traditional valuation multiples largely irrelevant for assessing the entity's true value.
Analysts should instead focus on the net asset value per share and the sponsor's historical success rate in executing accretive transactions. Relying on P/E ratios in this context may lead to a fundamental misunderstanding of the company's risk-reward profile, which is tied to deal-making rather than operational earnings.
Includes 30+ ratios · 2 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OACC stock.
Oaktree Acquisition Corp. III Life Sciences's current P/E ratio is 35.6x. The historical average is 109.5x. This places it at the 50th percentile of its historical range.
Oaktree Acquisition Corp. III Life Sciences's return on equity (ROE) is 3.8%. The historical average is 1.9%.
Based on historical data, Oaktree Acquisition Corp. III Life Sciences is trading at a P/E of 35.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.